• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2012 Product Image

Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2012

  • ID: 2245170
  • September 2012
  • 82 pages
  • Global Markets Direct

Leishmaniasis (Kala-Azar) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Leishmaniasis (Kala-Azar), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala-Azar). Leishmaniasis (Kala-Azar) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Leishmaniasis (Kala-Azar).
- A review of the Leishmaniasis (Kala-Azar) products under READ MORE >

2
List of Tables 7
List of Figures 7
Introduction 8
REPORT COVERAGE 8
Leishmaniasis (Kala-Azar) Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Leishmaniasis (Kala-Azar) 10
Leishmaniasis (Kala-Azar) Therapeutics under Development by Companies 12
Leishmaniasis (Kala-Azar) Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Pre-Clinical Stage Products 18
Comparative Analysis 18
Leishmaniasis (Kala-Azar) Therapeutics – Products under Development by Companies 19
Leishmaniasis (Kala-Azar) Therapeutics – Products under Investigation by Universities/Institutes 20
Companies Involved in Leishmaniasis (Kala-Azar) Therapeutics Development 21
Merck Serono S.A. 21
iCo Therapeutics Inc. 22
MOLOGEN AG 23
Dafra Pharma International Ltd. 24
aRigen Pharmaceuticals, Inc. 25
Leishmaniasis (Kala-Azar) – Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
miltefosine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
miltefosine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
azithromycin - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Miltefosine + Liposomal Amphotericin B - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
AmBisome + Miltefosine - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
amphotericin B lipid formulation - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Liposomal Amphotericin B + Miltefosine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Liposomal Amphotericin B + Paromomycin Sulfate - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Paromomycin Sulfate + Miltefosine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Miltefosine + Paromomycin Sulfate - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Leish-111f + MPL-SE - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
AmBisome + Paromomycin Sulfate - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
sodium stibogluconate - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
paromomycin - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Paromomycin + Gentamicin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
algeldrate - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
lipid-based amphotericin B - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
meglumine antimoniate - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
GMCSF + Antimony - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
LEISH-F2 + MPL-SE Vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
AmBisome + Sodium Stibogluconate - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
AmBisome + Miltefosine - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
miltefosine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
miltefosine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
MGN-1331 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
meglumine antimoniate - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Liposomal Azithromycin - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
miltefosine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
pentamidine - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Oleylphosphocholine - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
trichloroacetic acid - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
fexinidazole - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
AS-605240 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 71
vaccine for Leishmania - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Drug For Leishmaniasis - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Leishmaniasis (Kala-Azar) Therapeutics – Drug Profile Updates 74
Leishmaniasis (Kala-Azar) Therapeutics – Discontinued Products 75
Leishmaniasis (Kala-Azar) Therapeutics - Dormant Products 76
Leishmaniasis (Kala-Azar) – Product Development Milestones 77
Featured News & Press Releases 77
Feb 22, 2012: IDRI Launches First Clinical Trial For New Vaccine To Treat Leishmaniasis 77
Feb 02, 2012: University Of Dundee Researchers Identify Potential New Treatment For Leishmaniasis 78
Oct 24, 2011: iCo Therapeutics Oral Amphotericin B Delivery System To Be Presented At AAPS 78
Sep 29, 2010: iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status 79
Apr 06, 2010: MOLOGEN AG Receives Funding To Develop A DNA Vaccine Against Hepatitis B 79
Appendix 81
Methodology 81
Coverage 81
Secondary Research 81
Primary Research 81
Expert Panel Validation 81
Contact Us 82
Disclaimer 82

List of Tables
Number of Products Under Development for Leishmaniasis (Kala-Azar), H2 2012 10
Products under Development for Leishmaniasis (Kala-Azar) – Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 20
Merck Serono S.A., H2 2012 21
iCo Therapeutics Inc., H2 2012 22
MOLOGEN AG, H2 2012 23
Dafra Pharma International Ltd., H2 2012 24
aRigen Pharmaceuticals, Inc., H2 2012 25
Assessment by Monotherapy Products, H2 2012 26
Assessment by Combination Products, H2 2012 27
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Stage and Molecule Type, H2 2012 31
Leishmaniasis (Kala-Azar) Therapeutics – Drug Profile Updates 74
Leishmaniasis (Kala-Azar) Therapeutics – Discontinued Products 75
Leishmaniasis (Kala-Azar) Therapeutics – Dormant Products 76

List of Figures
Number of Products under Development for Leishmaniasis (Kala-Azar), H2 2012 10
Products under Development for Leishmaniasis (Kala-Azar) – Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 26
Assessment by Combination Products, H2 2012 27
Assessment by Route of Administration, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Molecule Type, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 31

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos